
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–AstraZeneca and Merck (NYSE: […]














